Thanks for visiting and learning more about Kadmon.
Kadmon is a biopharmaceutical company that discovers, develops and markets transformative therapies for unmet medical needs. Out clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. On July 16, 2021 the U.S. FDA approved REZUROCK™ (belumosudil) 200 mg tablets daily for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy.
Brands: REZUROCK™ (belumosudil)